A Pharmacovigilance Study in First Episode of Psychosis : Psychopharmacological Interventions and Safety Profiles in the PEPs Project
Bioque, Miquel (Hospital Clínic i Provincial de Barcelona)
Llerena, Adrián (Universidad de Extremadura)
Cabrera, Bibiana (Hospital Clínic i Provincial de Barcelona)
Mezquida, Gisela (Hospital Clínic i Provincial de Barcelona)
Lobo, Antonio (Universidad de Zaragoza)
González-Pinto, Ana (Arabako Unibertsitate Ospitalea (Vitoria, País Basc))
Díaz-Caneja, Covadonga M. (Hospital General Universitario Gregorio Marañón)
Corripio, Iluminada (Institut d'Investigació Biomèdica Sant Pau)
Aguilar, Eduardo J. (Hospital Clínic València)
Bulbena Vilarrasa, Antonio (Institut Hospital del Mar d'Investigacions Mèdiques)
Castro-Fornieles, Josefina (Hospital Clínic i Provincial de Barcelona)
Vieta, Eduard (Hospital Clínic i Provincial de Barcelona)
Lafuente, Amàlia (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Mas, Sergi (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Parellada, Mara (Hospital General Universitario Gregorio Marañón)
Saiz-Ruiz, Jerónimo (Hospital Ramon y Cajal)
Cuesta, Manuel J. (Instituto de Investigación Sanitaria de Navarra)
Bernardo, Miguel (Universitat de Barcelona)
Gassó, P.
Amoretti, S.
García Bernardo, E.
Tapia-Casellas, C.
Alonso-Solís, Anna (Institut d'Investigació Biomèdica Sant Pau)
Grasa, Eva (Institut d'Investigació Biomèdica Sant Pau)
Hernández, M.
González, I.
Ruiz, P.
Modrego, F.
Escartí, M.J.
Mané, Anna
Torrent, C.
Baeza, I.
Contreras, F.
Albacete, A.
Bobes, Julio
García-Portilla, Maria Paz
Zabala Rabadán, A.
Segarra Echevarría, R.
Rodriguez-Jimenez, R.
Morales-Muñoz, I.
Butjosa, A.
Landin-Romero, R.
Sarró, S.
Ibáñez, Á.
Sánchez-Torres, A.M.
Balanzá-Martínez, Vicent
Universitat Autònoma de Barcelona

Date:	2016
Abstract:	The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. The majority of first episode of psychosis patients received a second-generation antipsychotic (96. 3%), orally (95%), and in adjusted doses according to the product specifications (87. 2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=. 043). A total of 5. 2% of the patients were being treated with long-acting injectable antipsychotics; 12. 2% of the patients received anticholinergic drugs, 12. 2% antidepressants, and 13. 7% mood stabilizers, while almost 40% received benzodiazepines; and 35. 52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85. 2% vs 45. 5%, P<. 001). These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Antipsychotic ; First episode psychosis ; Pharmacovigilance ; Polytherapy ; Psychotropic drugs ; Schizophrenia
Published in:	International journal of neuropsychopharmacology, Vol. 19 Núm. 4 (january 2016) , ISSN 1469-5111

DOI: 10.1093/ijnp/pyv121
PMID: 26506856

10 p, 659.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles